BRAIN Biotech

行业

化妆品, 饲料, 工业化学

主题

酶与生物催化, 动物饲料与饲料添加剂, 透明质酸、胶原蛋白与化妆品生物活性成分

角色

生产商 — “…signed to move products and processes forward with innovative biosolutions. They position themselves as a part…”

为何属于生物经济

BRAIN Biotech 是工业生物技术公司，专注特种酶、微生物生产菌株和生物基方案的开发、生产与分销——服务食品、生命科学和环境领域。

尚未被列为已评级方案的供应商。

子公司: BRAIN UK II Ltd. · Biocatalysts Ltd. · Biocatalysts Inc. · WeissBioTech GmbH · Breatec B.V. · RMH AG · AnalytiCon Discovery LLC · Biosun Biochemicals Inc.

• 2026-10 最新状态: Sven K. Weber 博士被任命为新任执行董事会主席（CEO），2026年10月1日生效，接替 Adriaan Moelker。 ↗ ↗ ↗

近期新闻 5

由自动检索获得；摘要为机器生成的英文。标题含公司名称，或摘要以该公司为主体——引用前请核对原文。

• 2026-09-09 BRAIN Biotech AG Receives EUR 11.51 Million Major Milestone Payment from Royalty Pharma | Ad-hoc - EQS News eqs-news.com
  BRAIN Biotech AG has received an additional EUR 11.51 million milestone payment from Royalty Pharma for progress on the investigational compound deucrictibant, boosting expected future payments up to EUR 96.65 million. The deal also triggers a one-time non-cash IFRS 9 charge (up …
• 2026-09-09 BRAIN Biotech AG Receives EUR 11.51 Million Major Milestone Payment from Royalty Pharma | Ad-hoc - EQS News eqs-news.com
  BRAIN Biotech AG reports a new EUR 11.51 million milestone payment from Royalty Pharma tied to progress of the investigational drug deucrictibant, boosting expectations for further up to EUR 96.65 million in future milestones. It also notes a one-time non-cash IFRS 9 charge up to …
• 2026-07-29 Dr. Sven K. Weber Succeeds Adriaan Moelker as CEO of BRAIN Biotech AG | Corporate - EQS News eqs-news.com
  Dr. Brain Biotech AG will appoint Dr. Sven K. Weber as CEO (effective Oct 1, 2026), with current CEO Adriaan Moelker retiring by Jan 2027 but staying as a senior advisor until then; the company emphasizes continued growth in specialty enzymes, expansion via the BRAINBioIncubator, …
• 2026-07-13 BRAIN Biotech AG signs new Revolving Credit Facility with MP Beteiligungs-GmbH | Ad-hoc - EQS News eqs-news.com
  BRAIN Biotech AG has arranged a new €9.0 million revolving credit facility with MP Beteiligungs-GmbH, maturing December 31, 2028, with interest at 6-month Euribor plus 233 basis points, intended for general corporate financing and debt servicing.
• 2026-05-28 BRAIN Biotech AG reports half-year figures for fiscal year 2025/26 and confirms full year guidance | BRAIN Biotech Group brain-biotech-group.com
  BRAIN Biotech reports first-half 2025/26 revenue of €23.4m (down 7.2% YoY) with adjusted EBITDA near break-even (-€0.1m) and notes production relocations affecting Biocatalysts sales, while highlighting strong progress in its BRAINBioIncubator with a granted CRISPR nuclease …

股权与投资方 8

合作与交易 1

同类企业

Biocatalysts Ltd · c-LEcta GmbH · Biocatalysts Baking · Leaf by Lesaffre · Biocatalysts Beverages · BiCT srl - Biological and Chemical Technologies · Bio Base Europe Pilot Plant · Global BioTech S.L